

Date: 7th November, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir / Madam,

Sub: Outcome of Board Meeting

With reference to the captioned subject, the exchanges are hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter-alia approved the Unaudited Financial Results for the quarter and half year ended 30th September, 2024.

We enclose herewith the following:

- a) i) Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2024.
ii) Consolidated Statement of Assets and Liabilities as at 30th September 2024.
iii) Consolidated Cash Flow Statements for the half year ended 30th September 2024.
- b) i) Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2024.
ii) Standalone Statement of Assets and Liabilities as at 30th September 2024.
iii) Standalone Cash Flow Statements for the half year ended 30th September 2024.
- c) Limited Review Report by Statutory Auditors on the Consolidated and Standalone Unaudited Financial Results.

The time of commencement of the Board Meeting was 11:15 a.m. and the time of conclusion was 1:00 p.m.



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-265-2280550 • FAX : +91-265-2282837
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in
CIN: L24230GJ2010PLC061123


We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited


Manisha Saraf
Company Secretary



Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-265-2280550 • FAX : +91-265-2282837

Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123

Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2024

	Particulars	Quarter Ended			Half Year Ended		Rs. in Crores
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	Revenue from Operations	1,647.98	1,561.73	1,594.93	3,209.71	3,081.08	6,228.63
2	Other Income	16.74	2.10	10.15	18.85	21.82	28.31
3	Total Income	1,664.72	1,563.83	1,605.08	3,228.55	3,102.90	6,256.93
4	Expenses						
	(a) Cost of Materials consumed	393.14	405.93	413.87	799.07	748.06	1,403.01
	(b) Purchase of stock-in-trade	102.64	95.50	88.68	198.14	178.92	454.91
	(c) Changes in Inventories of finished goods, Stock in trade and WIP	(66.66)	(107.34)	(41.12)	(174.00)	(52.02)	(142.84)
	(d) Employee benefits expense	391.47	379.77	346.99	771.24	695.16	1,446.29
	(e) Finance Costs	18.81	13.18	15.69	31.99	30.08	56.19
	(f) Depreciation & Amortization Expense	70.51	69.04	67.56	139.55	133.74	272.67
	(g) Other Expenses	588.13	551.04	578.26	1,139.17	1,104.03	2,133.90
	Total Expenses	1,498.03	1,407.12	1,469.94	2,905.16	2,837.96	5,624.13
5	Profit before Share of Profit / (Loss) of Associates and Joint Ventures	166.69	156.71	135.15	323.40	264.93	632.80
6	Share of Profit / (Loss) of Associates & Joint Ventures	0.86	0.32	(0.51)	1.18	(0.54)	(0.98)
7	Profit Before Exceptional Item and Tax	167.55	157.03	134.64	324.58	264.40	631.83
8	Exceptional Item - Refer Note No 3 & 4	12.87	-	-	12.87	-	-
9	Profit Before Tax	180.42	157.03	134.64	337.45	264.40	631.83
10	Tax Expense						
	(i) Current Tax	40.23	38.82	3.54	79.05	7.84	65.81
	(ii) Deferred Tax	(12.95)	(16.33)	(5.46)	(29.29)	(0.60)	(46.06)
	(iii) Short / (Excess) Tax Provision	0.00	-	-	0.00	-	(3.75)
11	Profit for the Period before non-controlling interests	153.14	134.54	136.56	287.69	257.16	615.82
12	Non-controlling interests	0.26	0.17	-	0.43	-	-
13	Profit for the Period after non-controlling interests	153.41	134.71	136.56	288.12	257.16	615.82
14	Other Comprehensive Income						
A	(i) Items that will not be reclassified to profit / (loss)	0.26	(3.90)	(2.01)	(3.64)	(2.10)	(15.60)
	(ii) Income tax relating to items that will not be reclassified to profit / (loss)	(0.05)	0.68	-	0.64	-	0.99
B	(i) Items that will be reclassified to profit / (loss)	1.09	(0.12)	2.58	0.98	1.73	3.77
	Total Other Comprehensive Income (A+B)	1.31	(3.34)	0.57	(2.03)	(0.37)	(10.84)
15	Total Comprehensive Income for the period (11+14)	154.45	131.21	137.12	285.66	256.79	604.98
	Attributable to:						
	- Non-controlling interests	(0.25)	(0.17)	-	(0.42)	-	-
	- Owners of the Company	154.71	131.37	137.12	286.08	-	604.98
16	Earnings per share - Basic & Diluted (in Rs.)	7.79	6.84	6.95	14.64	13.08	31.33
17	Paid up Equity Share Capital (Face Value of Rs 2/- each)	39.31	39.31	39.31	39.31	39.31	39.31
18	Other Equity						4,778.89



Notes :

- 1 The above consolidated results, have been reviewed by the Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
- 3 The Company's formulation manufacturing operations in Sikkim were disrupted by flash floods on October 4, 2023, got fully resumed in February 2024. The insurance company has approved total final claim of Rs. 83.61 crores on reinstatement value of Property, Plant & Equipment and loss of profit due to business interruption. The claims inter alia include Rs. 5.92 crores for damages to Property, Plant and Equipment, Rs. 34.72 crores for lost inventories and Rs. 30.10 crores for restoration and other expenditures. The company has received full approved insurance claim as on date. As a result of above, net income of Rs. 12.87 crores has been recognised under Exception Items in the Statement of Profit and Loss for the period ended September 30, 2024.
- 4 Exceptional items pertaining to previous periods include the write-off of identified CWIP amounting to Rs. 173.50 crores for September'23 quarter, Rs. 81.71 crores for June'23 quarter i.e Rs 255.21 crores for Half year ended 30th September, 2023 and Rs. 473.56 crores for the year ended 31st March, 2024, against the provision of impairment already created in March 2023. There is no impact on current or previous period's profit.
- 5 Disclosures as per Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable and additional informations are given hereunder:

Sr. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
a	Debt-Equity Ratio (in times) Debt / Net Worth [Debt : Total Debt (Short term + Long term) Net worth : Share Capital + Other Equity]	0.20	0.12	0.18	0.20	0.18	0.09
b	Debt Service Coverage Ratio (in times) (Profit before tax+interest) / (Interest + schedule principal repayments of Long term debt) Annualised	10.59	12.91	9.58	11.55	9.79	12.24
c	Interest Service Coverage Ratio (in times) (Profit before tax+interest)/ Interest	10.59	12.91	9.58	11.55	9.79	12.24
d	Net Worth (Rs. in Crores) (Equity capital + Other Equity excluding fair value change on financial Instruments through OCI)	4,900.58	4,962.09	4,469.44	4,900.58	4,469.44	4,830.72
e	Current Ratio (in times) Current Asset / Current Liabilities	1.73	1.97	1.73	1.73	1.73	2.12
f	Bad Debts to Accounts Receivable Ratio (%) Bad Debts / Accounts Receivable	0.41%	0.00%	0.06%	0.41%	0.06%	0.28%
g	Current Liability Ratio (in times) Current Liabilities / Total Liabilities	0.93	0.92	0.91	0.93	0.91	0.89
h	Total Debts to Total Assets (in times) (Long term Borrowings + Short Term Borrowings+ Lease liability)/ Total Assets	0.15	0.10	0.13	0.15	0.13	0.08
i	Debtors Turnover Ratio (in times) (Value of Sales and Service / Average Debtor) Annualised	5.69	5.81	5.96	5.55	5.76	5.92
j	Inventory Turnover (in times) (Sale of products / Average WIP, FG and Stock in trade Inventory) Annualised	5.39	5.25	6.28	5.24	6.07	5.83
k	Operating Margin (%) EBITDA / Revenue from Operations	15.60%	15.32%	13.66%	15.47%	13.90%	15.42%
l	Net Profit Margin (%) (Net Profit after taxes and share of Profit/(Loss) of Associates and Joint Ventures)/ Revenue from Operations	9.31%	8.61%	8.56%	8.98%	8.35%	9.89%

- 6 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / period.



For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 7th November, 2024


Chirayu Amin
Chairman and CEO

Visit us at www.alembicpharmaceuticals.com

Alembic Pharmaceuticals Limited

Statement of Assets and Liabilities - Consolidated

Rs. in Crores

Particulars	As at 30th September, 2024 (Unaudited)	As at 31st March, 2024 (Audited)
A ASSETS		
1 Non-current assets		
(a) Property, plant and equipment	2,463.23	2,546.71
(b) Capital work-in-progress	661.63	524.36
(c) Financial Assets		
(i) Investments	76.09	68.61
(ii) Investment accounted for using Equity Method	25.67	24.41
(d) Deferred tax assets (net)	199.32	169.64
(e) Other non-current assets	41.90	33.30
2 Current assets		
(a) Inventories	2,012.52	1,643.54
(b) Financial Assets		
- Trade receivables	1,267.68	1,024.84
- Cash and cash equivalents	122.05	120.21
- Bank balances other than cash and cash equivalents	6.90	6.36
- Other financial assets	20.32	20.77
(c) Current Tax Assets (Net)	27.81	41.03
(d) Other current assets	305.11	221.81
TOTAL - ASSETS	7,230.25	6,445.58
B EQUITY AND LIABILITIES		
1 Equity		
(a) Equity Share capital	39.31	39.31
(b) Other Equity	4,848.75	4,778.89
	4,888.06	4,818.20
(c) Non-controlling interests	(0.42)	-
Total Equity	4,887.64	4,818.20
2 Non-current liabilities		
(a) Financial liabilities		
- Lease liabilities	53.43	62.88
(b) Provisions	117.36	109.51
3 Current liabilities		
(a) Financial liabilities		
- Borrowings	994.95	430.45
- Lease liabilities	17.97	19.83
- Trade payables		
A) Due to Micro and Small Enterprises	31.44	25.44
B) Due to other than Micro and Small Enterprises	857.79	710.20
- Other financial liabilities	138.15	143.87
(b) Other current liabilities	69.44	59.95
(c) Provisions	62.08	65.25
TOTAL - EQUITY AND LIABILITIES	7,230.25	6,445.58

Place : Vadodara
Date : 7th November, 2024



For Alembic Pharmaceuticals Limited




Chirayu Amin
Chirayu Amin
Chairman and CEO

Visit us at www.alembicpharmaceuticals.com

Particulars	For the Half	For the Half Year
	Year ended 30th September, 2024 (Unaudited)	ended 30th September, 2023 (Unaudited)
A CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Profit Before Tax as per Statement of Profit and Loss (After Exceptional item)	337.45	264.40
Adjustments for:		
Share of (Profit) / Loss of Associates and Joint Ventures	(1.18)	0.54
Depreciation and amortisation	139.55	133.74
Interest Expense	31.99	30.08
Interest Income	(0.72)	(1.85)
Dividend Income / Gain on Sale of Investments	(0.74)	(0.70)
Unrealised foreign exchange (gain) / loss (net)	20.91	(35.26)
Fair value (gain)/ loss on financial instruments at fair value through profit or loss	(2.48)	(1.84)
Provision / write off for doubtful trade receivables	0.45	0.26
Sundry balances written off / written-back (net)	0.00	(0.01)
Loss/(Profit) on sale of Asset	0.00	(2.33)
Operating Profit before change in working capital	525.23	387.01
Working capital changes:		
(Increase) In Inventories	(368.98)	(63.98)
(Increase) In Trade Receivables	(257.70)	(9.30)
(Increase) In Other Assets	(75.05)	(73.29)
Increase In Trade Payables	153.93	82.80
Increase In Other Liabilities	(14.43)	(27.83)
Increase/(Decrease) In Provisions	1.03	(4.88)
Cash generated from operations	(35.97)	290.54
Direct taxes paid (Net)	(65.00)	2.47
Net Cash inflow from Operating Activities (A)	(100.97)	293.01
B CASH FLOWS FROM INVESTING ACTIVITIES:		
Proceeds from Sale of Asset	0.00	11.40
Interest received	0.72	1.85
Dividend / Gain on Sale of Investments received	0.74	0.70
Purchase of Property, Plant & Equipments, Intangible Assets and Capital Advance	(190.03)	(189.39)
Investment in Alternative Investment Equity Fund	(5.00)	-
Net Cash inflow from Investing Activities (B)	(193.57)	(175.43)
C CASH FLOWS FROM FINANCING ACTIVITIES:		
Net Increase in short term borrowings	564.50	148.51
Payment of lease liabilities	(14.09)	(13.60)
Change in Restricted Bank Balances other than Cash & Cash Equivalents	(1.42)	(0.01)
Dividends paid	(216.22)	(157.25)
Interest and other finance costs	(36.39)	(29.41)
Net Cash inflow from Financing Activities (C)	296.38	(51.76)
I Net (Decrease)/Increase in cash and cash equivalents (A+B+C)	1.84	65.82
II. a) Cash and cash equivalents at the beginning of the Year	120.21	75.48
II. Cash and cash equivalents at the end of the period (I+II)	122.05	141.30
IV. Cash and cash equivalents at the end of the period	121.82	140.95
Balances with Banks	0.23	0.35
Cash on hand	122.05	141.30
Cash and cash equivalents	122.05	141.30

For Alembic Pharmaceuticals Limited




Chirayu Amin
Chairman and CEOPlace : Vadodara
Date : 7th November, 2024Visit us at www.alembicpharmaceuticals.com

Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2024

Rs. in Crores

	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	Revenue from Operations	1,580.35	1,475.56	1,478.84	3,055.91	2,811.11	5,874.06
2	Other Income	16.06	3.15	8.95	19.20	20.80	31.32
3	Total Income	1,596.41	1,478.70	1,487.79	3,075.11	2,831.91	5,905.38
4	Expenses						
	(a) Cost of Materials consumed	393.14	405.93	413.87	799.07	748.06	1,403.01
	(b) Purchase of stock-in-trade	96.10	94.36	85.68	190.46	175.63	449.70
	(c) Changes in Inventories of finished goods, Stock in trade and WIP	(17.19)	(111.68)	(30.07)	(128.87)	(37.27)	(52.36)
	(d) Employee benefits expense	367.61	356.51	326.41	724.13	653.87	1,335.91
	(e) Finance Costs	18.28	12.69	15.39	30.97	29.68	54.47
	(f) Depreciation & Amortization Expense	70.12	68.68	67.18	138.80	132.94	271.14
	(g) Other Expenses	481.20	439.01	475.50	920.21	897.63	1,739.28
	Total Expenses	1,409.26	1,265.50	1,353.95	2,674.76	2,600.54	5,201.15
5	Profit Before Exceptional Item and Tax	187.15	213.20	133.84	400.35	231.37	704.23
6	Exceptional Item - Refer Note No 2 & 3	12.87	-	-	12.87	-	-
7	Profit Before Tax	200.02	213.20	133.84	413.22	231.37	704.23
8	Tax Expense						
	(i) Current Tax	34.24	37.01	-	71.25	-	41.50
	(ii) Short / (Excess) Tax Provision	0.00	-	-	0.00	-	(3.75)
9	Profit for the Period	165.78	176.19	133.84	341.97	231.37	666.48
10	Other Comprehensive Income						
	(i) Items that will not be reclassified to profit / (loss)	0.26	(3.90)	(2.01)	(3.64)	(2.10)	(15.60)
	(ii) Income tax relating to items that will not be reclassified to profit / (loss)	(0.05)	0.68	-	0.64	-	0.99
11	Total Comprehensive Income for the period	166.00	172.97	131.83	338.97	229.27	651.87
12	Earnings per share - Basic & Diluted (in Rs.)	8.43	8.96	6.81	17.40	11.77	33.91
13	Paid up Equity Share Capital (Face Value of Rs 2/- each)	39.31	39.31	39.31	39.31	39.31	39.31
14	Other Equity						4,869.60



Notes :

- 1 The above standalone results, have been reviewed by the Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- 2 The Company's formulation manufacturing operations in Sikkim were disrupted by flash floods on October 4, 2023, got fully resumed in February 2024. The insurance company has approved total final claim of Rs. 83.61 crores on reinstatement value of Property, Plant & Equipment and loss of profit due to business interruption. The claims inter alia include Rs. 5.92 crores for damages to Property, Plant and Equipment, Rs. 34.72 crores for lost inventories and Rs. 30.10 crores for restoration and other expenditures. The company has received full approved insurance claim as on date. As a result of above, net income of Rs. 12.87 crores has been recognised under Exception Items in the Statement of Profit and Loss for the period ended September 30, 2024.
- 3 Exceptional items pertaining to previous periods include the write-off of identified CWIP amounting to Rs. 173.50 crores for September'23 quarter, Rs. 81.71 crores for June'23 quarter i.e Rs 255.21 crores for Half year ended 30th September, 2023 and Rs. 473.56 crores for the year ended 31st March, 2024, against the provision of impairment already created in March 2023. There is no impact on current or previous period's profit.
- 4 Disclosures as per Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable and additional informations are given hereunder:

Sr. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
a	Debt-Equity Ratio (in times) Debt / Net Worth [Debt : Total Debt (Short term + Long term) Net worth : Share Capital + Other Equity]	0.19	0.11	0.17	0.19	0.17	0.09
b	Debt Service Coverage Ratio (in times) (Profit before tax+interest) / (Interest + schedule principal repayments of Long term debt) Annualised	11.94	17.80	9.70	14.34	8.80	13.93
c	Interest Service Coverage Ratio (in times) (Profit before tax+interest) / Interest	11.94	17.80	9.70	14.34	8.80	13.93
d	Net Worth (Rs. in Crores) (Equity capital + Other Equity excluding fair value change on financial Instruments through OCI)	5,044.19	5,094.41	4,485.74	5,044.19	4,485.74	4,921.44
e	Current Ratio (in times) Current Asset / Current Liabilities	1.83	2.08	1.74	1.83	1.74	2.25
f	Bad Debts to Accounts Receivable Ratio (%) Bad Debts/ Accounts Receivable	0.32%	0.00%	0.06%	0.32%	0.06%	0.05%
g	Current Liability Ratio (in times) Current Liabilities / Total Liabilities	0.93	0.92	0.91	0.93	0.91	0.89
h	Total Debts to Total Assets (in times) (Long term Borrowings + Short Term Borrowings+ Lease liability)/ Total Assets	0.14	0.09	0.13	0.14	0.13	0.08
i	Debtors Turnover Ratio (in times) (Value of Sales and Service / Average Debtor) Annualised	4.22	4.15	4.86	4.08	4.62	4.55
j	Inventory Turnover (in times) (Sale of products / Average WIP, FG and Stock in trade Inventory) Annualised	6.97	6.56	7.32	6.73	6.96	7.16
k	Operating Margin (%) EBITDA / Revenue from Operations	17.44%	19.96%	14.63%	18.66%	14.02%	17.53%
l	Net Profit Margin (%) Net Profit after taxes / Revenue from Operations	10.49%	11.94%	9.05%	11.19%	8.23%	11.35%

- 5 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / period.



For Alembic Pharmaceuticals Limited

Chirayu Amin
Chairman and CEO


Place : Vadodara
Date : 7th November, 2024

Visit us at www.alembicpharmaceuticals.com

Statement of Assets and Liabilities - Standalone

Rs. in Crores

Particulars		As at 30th September, 2024 (Unaudited)	As at 31st March, 2024 (Audited)
A	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	2,452.74	2,535.66
	(b) Capital work-in-progress	661.63	524.36
	(c) Financial Assets		
	(i) Investments	234.17	226.68
	(ii) Loan	71.57	11.16
	(d) Deferred tax assets (net)	78.83	78.83
	(e) Other non-current assets	41.90	33.30
2	Current assets		
	(a) Inventories	1,676.82	1,353.07
	(b) Financial Assets		
	- Trade receivables	1,625.11	1,340.12
	- Cash and cash equivalents	13.86	20.13
	- Bank balances other than cash and cash equivalents	6.90	6.36
	- Others financial assets	19.68	20.28
	(c) Current Tax Assets (Net)	30.89	49.30
	(d) Other current assets	279.69	199.30
	TOTAL - ASSETS	7,193.80	6,398.54
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share capital	39.31	39.31
	(b) Other Equity	4,992.35	4,869.60
2	Non-current liabilities		
	(a) Financial liabilities		
	- Lease liabilities	43.92	52.91
	(b) Provisions	117.36	109.51
3	Current liabilities		
	(a) Financial liabilities		
	- Borrowings	980.00	420.04
	- Lease liabilities	16.97	19.04
	- Trade payables		
	A) Due to Micro and Small Enterprises	31.44	25.44
	B) Due to other than Micro and Small Enterprises	703.82	594.52
	- Other financial liabilities	137.88	143.62
	(b) Other current liabilities	69.31	59.67
	(c) Provisions	61.45	64.88
	TOTAL - EQUITY AND LIABILITIES	7,193.80	6,398.54



For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 7th November, 2024


Chirayu Amin
Chairman and CEO


Visit us at www.alembicpharmaceuticals.com

Alembic Pharmaceuticals Limited

Standalone Statement of Cash Flows For the Half Year ended 30th September, 2024

Rs. In Crores

Particulars	For the Half	For the Half Year
	Year ended 30th September, 2024 (Unaudited)	ended 30th September, 2023 (Unaudited)
A CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Profit Before Tax as per Statement of Profit and Loss (After Exceptional item)	413.22	231.37
Adjustments for:		
Depreciation and amortisation	138.80	132.94
Interest Expense	30.97	29.68
Interest Income	(1.78)	(2.21)
Dividend Income / Gain on Sale of Investments	(0.74)	(0.70)
Unrealised foreign exchange (gain) / loss (net)	20.91	(35.26)
Fair value (gain)/ loss on financial instruments at fair value through profit or loss	(2.48)	(1.84)
Provision / write off for doubtful trade receivables	0.45	0.26
Sundry balances written off / written-back (net)	0.00	(0.01)
Loss/(Profit) on sale of Asset	0.00	(0.06)
Operating Profit before change in working capital	599.34	354.16
Working capital changes:		
(Increase) In Inventories	(323.75)	(49.33)
(Increase)/Decrease In Trade Receivables	(300.68)	7.74
(Increase) In Other Assets	(72.00)	(61.13)
Increase In Trade Payables	115.63	47.81
Increase/(Decrease) In Other Liabilities	(14.30)	(27.84)
Increase/(Decrease) In Provisions	0.78	(5.00)
Cash generated from operations	5.02	266.40
Direct taxes paid (Net)	(52.21)	5.28
Net Cash inflow from Operating Activities (A)	(47.19)	271.68
B CASH FLOWS FROM INVESTING ACTIVITIES:		
Proceeds from Sale of Asset	0.00	0.08
Loan to subsidiary company (Net)	(58.57)	0.00
Interest received	0.09	1.85
Dividend / Gain on Sale of Investments received	0.74	0.70
Purchase of Property, Plant & Equipment and Capital Advance	(190.32)	(187.51)
Investment in Alternative Investment Equity Fund	(5.00)	-
Net Cash inflow from Investing Activities (B)	(253.05)	(184.88)
C CASH FLOWS FROM FINANCING ACTIVITIES:		
Net Increase in working capital demand loans	559.96	144.93
Payment of lease liabilities	(12.52)	(12.04)
Increase in Restricted Bank Balances other than Cash & Cash Equivalents	(1.42)	(0.01)
Dividends paid	(216.22)	(157.25)
Interest and other finance costs	(35.83)	(29.45)
Net Cash inflow from Financing Activities (C)	293.97	(53.83)
I Net (Decrease)/Increase in cash and cash equivalents (A+B+C)	(6.27)	32.97
II. a) Cash and cash equivalents at the beginning of the Year	20.13	21.67
II. b) Cash and cash equivalents at the end of the period (I+II)	13.86	54.64
IV. Cash and cash equivalents at the end of the period		
Balances with Banks	13.63	54.34
Cash on hand	0.23	0.30
Cash and cash equivalents	13.86	54.64



For Alembic Pharmaceuticals Limited

Chirayu Amin
Chirayu Amin
Chairman and CEO

Place : Vadodara
Date : 7th November, 2024

Visit us at www.alembicpharmaceuticals.com

to the amounts and disclosures included in respect of this subsidiary, is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter with respect to our reliance on the work done by and report of the other auditor.

7. The Statement includes the interim financial results of 3 subsidiaries which have not been reviewed by their respective auditors, whose interim financial results reflect total assets of Rs. 299.39 crores as at September 30, 2024, total revenues of Rs. 175.85 crores and Rs. 289.79 crores for the quarter and half year ended September 30, 2024 respectively, total net profit/(loss) after tax of Rs. 2.22 crores and Rs. (0.55) crores for the quarter and half year ended September 30, 2024 respectively, total comprehensive income/(loss) of Rs. 2.61crores and Rs. (0.02) crores for the quarter and half year ended September 30, 2024 and net cash inflow of Rs. 16.67 crores for the half year ended September 30, 2024 as considered in the Statement. The Statement also includes the Group's share of profit after tax of Rs. 0.86crores and Rs. 0.95 crores for the quarter and half year ended September 30, 2024 respectively and total comprehensive income of Rs. 0.86 crores and Rs. 95 crores for the quarter and half year ended September 30, 2024, as considered in the Statement, in respect of 1 associate, based on its interim financial results which have not been reviewed by respective auditor and whose interim financial results have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associate, are based solely on such unreviewed interim financial information/results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of this matter.

8. The Holding Company's management has converted the interim financial results of 4 subsidiaries, which are located outside India, from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries is based on the review report of such other auditor and Management certified interim financial results as referred in above paras and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion on the Statement is not modified in respect of this matter.

For K C Mehta & Co LLP
Chartered Accountants
Firm's Registration No. 106237W/W100829



Shripal Shah
Partner

Membership No. 114988
UDIN: 24114988BKAMCS7626
Place: Vadodara
Date: November 7, 2024



Annexure A

Details of entities included in unaudited consolidated financial results of the Alembic Pharmaceuticals Limited for the quarter and half year ended September 30, 2024

Sr. No.	Name of Entity	Relation	Consolidated /Standalone	Included in consolidation	Whether reviewed by other auditors
1	Alembic Pharmaceutical Inc.	Subsidiary	Consolidated	Yes	Yes
a.	Okner Realty LLC ¹	Step down subsidiary			
b.	Alembic Labs LLC ²	Step down subsidiary			
2	Alembic Global Holding SA (AGH)	Subsidiary	Consolidated	Yes	No
a.	Alembic Pharmaceuticals Australia Pty Ltd	Step down subsidiary			
b.	Alembic Pharmaceuticals Canada Ltd	Step down subsidiary			
c.	Alembic Pharmaceuticals Europe Limited	Step down subsidiary			
d.	Alnova Pharmaceuticals SA	Step down subsidiary			
e.	Genius LLC ³	Step down subsidiary			
f.	TicTwo Therapeutics Inc.	Step down subsidiary			
g.	Rhizen Pharmaceuticals AG	Associate of AGH			
h.	Dahlia Therapeutics SA	Associate as a subsidiary of Rhizen Pharmaceuticals AG			
i.	Rhizen Pharmaceuticals Inc. ⁴	Associate as a subsidiary of Rhizen Pharmaceuticals AG			
j.	Alembic Mami SPA ⁵	Joint Venture			
k.	SPH Sine Alembic (Shanghai) Pharmaceutical Technology Limited ⁶	Joint Venture			
3	Alembic Pharmaceuticals SPA	Subsidiary	Standalone	Yes	No
4	Alembic Pharmaceuticals S.A. de C.V.	Subsidiary	Standalone	Yes	No
5	Incozen Therapeutics Private Ltd	Associate	Standalone	Yes	No

¹The entity was dissolved on September 19, 2024.

² The entity was dissolved on September 26, 2024.

³ Genius LLC is based out in Ukraine. The investment value in Genius LLC is already provided for by AGH during FY 2022-2023. As at September 30, 2024, Genius LLC does not have any asset/liability and no transaction is entered during the current quarter. Formal legal process for liquidation is yet to be initiated by the Parent Company.

⁴ The entity is dissolved during FY 2022-2023. The Parent Company has written off the investments during March 2023 quarter. Accordingly, the same is not required to be consolidated as at September 30, 2024.



K C Mehta & Co LLP (LLPIN – ABB-3171) is registered as Partnership with limited liability

Regd Office: Meghdhanush, Race Course, Vadodara - 390 007 | **Branches:** Ahmedabad • Bengaluru • Mumbai

Phone: +91 265 2440400 | e-mail: connect@kcmehta.com | website: www.kcmehta.com

K C Mehta & Co LLP

Chartered Accountants

⁵ The consolidated unaudited financial results do not include share of profit or loss as the financial results of the same have not been received or prepared by the Alembic Global Holdings SA and no further share of loss is required to be borne by the Group as the entire Equity capital and loan given to it is fully provided for in earlier year. Formal legal process for dis-association is still to be initiated by the Parent Company.

⁶ The consolidated unaudited financial results do not include share of profit or loss in respect of a joint venture, agreement of which was entered into on May 7, 2019. We are informed that the Group has invested Rs. 0.46 Crores and the operations have not started till September 30, 2024 and therefore, there are no transactions for the quarter/period. The Joint Venture is in the process of product registration and will take due course of time for registration and operations way forward.



Independent Auditor's Review Report on the Interim Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 and Regulation 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Alembic Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Alembic Pharmaceuticals Limited** ("the Company") for the quarter and half year ended September 30, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ("Ind AS") 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India ("ICAI"). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the company's personnel responsible for financial and accounting matters and applying analytical procedures and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all the significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K C Mehta & Co LLP
Chartered Accountants
Firm's Registration No. 106237W/W100829



Shripal Shah
Partner
Membership No. 114988
UDIN: 24114988BKAMCR8408
Place: Vadodara
Date: November 7, 2024

